Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab vs Certolizumab Pegol in Active Ankylosing Spondylitis
NCT03215277Phase 2Completed
- Sponsor
- UCB
- Start
- Oct 2017
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of bimekizumab in ankylosing spondylitis (AS), sponsored by UCB. Started Oct 2017; status: completed.
02
Drugs
bimekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03215277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215277.